Latest Convertible Notes News

I Synergy Group Limited has formalised a strategic AI infrastructure agreement with Treasure Global Inc. and launched a partnership with Octagram Investment Limited, signalling early moves into AI-powered digital technologies.

Dundas Minerals advances its gold exploration with AI-driven targeting at the vast Gerry Well Greenstone Belt, appoints new Managing Director Jonathan Downes, and secures $1.12 million in fresh funding.

First Graphene Limited has reported its strongest first quarter sales ever for its PureGRAPH products, alongside new product launches and strategic partnerships that position it at the forefront of advanced materials innovation.

Beonic Limited has locked in a $7.3 million contract for its North African Airport Project following a successful proof of concept, while reporting improved gross margins and positive cash flow in Q1 FY26. The company also completed a $4.3 million capital raise to support growth and innovation.

Energy Technologies Limited reported a 33.4% increase in quarterly cash receipts alongside a 55% reduction in cash outflows for 1Q FY2026, signaling improved operational efficiency and liquidity management.

Dotz Nano has secured its first commercial order for its advanced carbon capture sorbent and raised A$1.2 million to accelerate development of its DotzEarth technology, marking a pivotal step towards commercialization in the growing DAC market.

Anax Metals has made significant progress on its Whim Creek Copper-Zinc project, securing a waste rock processing agreement and continuing efforts to finalize project financing.

CONNEQT Health reports robust 50% quarter-on-quarter growth in Pulse device sales and launches a new pricing strategy to boost recurring revenue. The company also secures a significant US clinical trial contract and advances cost-cutting efforts.

CONNEQT Health reported a $2.6 million operating cash outflow in the September quarter but secured $2 million through a convertible note, while expecting a $1.6 million R&D tax refund to shore up liquidity.

Paradigm Biopharmaceuticals has initiated dosing in its pivotal Phase 3 trial for knee osteoarthritis pain, backed by a strong cash position and strategic portfolio expansion. The company targets accelerated recruitment and a mid-2026 interim analysis.

Noxopharm Limited reports growing interest in its Sofra technology with new research collaborations and a safe, well-tolerated HERACLES trial of SOF-SKN. The company also secures funding extensions to support ongoing development.

Sprintex Limited has transitioned from development to commercial execution, securing major contracts in Europe, China, and India while raising A$1.5m to fund expansion.